Optimi Ships Psilocybin to the UK for Phase 2 Trial

VANCOUVER – Optimi Health Corp. announced it has completed its first export of naturally derived psilocybin to the United Kingdom, with the material earmarked for a planned Phase 2 clinical trial whose partner and therapeutic indication have not yet been disclosed.

The shipment includes psilocybin biomass and finished 5mg capsules – the same formulation currently prescribed to patients in Australia for treatment-resistant depression (TRD). It was manufactured at Optimi’s GMP facility in Princeton, British Columbia, and cleared under export authorization from Health Canada and import authorization from the UK Home Office.

That dual authorization matters. Psilocybin remains a Schedule I substance in the UK, placing it among the most tightly controlled compounds under British drug law. Institutions seeking to work with Schedule I drugs must hold a Home Office license, a requirement that researchers and universities have described as time-consuming, expensive, and logistically demanding. Obtaining an import authorization for a commercial GMP supplier to bring finished capsules into the country is a meaningful step within that framework.

Optimi cultivated the biomass and produced the capsules in-house, extracting the active pharmaceutical ingredient using its proprietary methods, all under its Health Canada Drug Establishment License. The company describes its ability to supply both biomass and finished drug product from a single licensed facility as a vertically integrated position in the regulated psychedelics supply chain.

The export follows Optimi’s recently announced completion of a GMP production run of its 5mg psilocybin drug product, a portion of which was set aside to support clinical research in Europe. The company is also active in Canada through the Special Access Program and in Australia, where its capsules are prescribed under the country’s Authorized Prescriber Scheme. Australia’s Therapeutic Goods Administration (TGA) recently expanded that scheme, broadening therapist eligibility for prescribing both psilocybin and MDMA for specific mental health conditions – a shift that followed a consultation process concluded in May 2026.

The commercial logic here is straightforward. A GMP manufacturer that can satisfy both a live patient market and a new clinical trial from the same facility, under a single license, carries a structural cost and speed advantage over competitors that must separate those operations. What makes this shipment notable is less the product itself [the 5mg capsule formulation is not new] and more the regulatory path it traveled to get there. UK Home Office import authorization for a finished psilocybin drug product from a foreign commercial supplier is not routine. For Optimi, this creates a reference point that may prove useful as additional European trial opportunities open up. The trial partner disclosure, when it comes, will be the next data point worth watching.